The Gamma Knife
The Gamma Knife is the worldwide radiosurgical leader in the non-invasive treatment of malignant and benign brain tumors, vascular malformations, and trigeminal neuralgia.

Track Record

The Gamma Knife's impressive accuracy and safety record spans four decades. More than 500,000 patients in over 250 select facilities worldwide have been treated with this technology, and patient outcomes have been documented in over 2,500 clinical publications.

This device has an impressive record of success in treating malignant brain tumors, trigeminal neuralgia, vascular malformations, and benign tumors such as acoustic neuromas, meningiomas, and pituitary adenomas. It has also been used successfully to treat lung, breast, kidney, and colon tumors, as well as melanomas that have metastasized to the brain. Although often the primary treatment, it can also be used to enhance the results of traditional brain surgery, radiation therapy, and chemotherapy.

Over time after treatment, tumor growth usually stops or is reduced and blood vessel abnormalities occlude and dissolve. Many patients experience increased life expectancy and improved quality of life.

Following are treatment results for specific conditions:

Metastatic tumors: Gamma Knife radiosurgery achieves control rates of 92 percent, essentially comparable to open surgery – but without the risk of infection, bleeding or complications - and without a lengthy hospital stay and convalescence.

Trigeminal neuralgia: Trigeminal Neuralgia symptoms typically manifest as a sharp, episodic, shooting pain on one side of the face. It has been reported that in 84 percent of cases treated by the Gamma Knife, patients have experienced pain relief for more than two years without reoccurrence.

Acoustic neuromas (vestibular schwannomas): Up to 93 percent of tumors either decrease in size or remain stable, with near complete facial nerve preservation, over at least two to five years.

Pituitary adenomas: Successful treatment in 80 percent of patients, measured in terms of reduced tumor size and/or hormonal levels or unchanged tumor size with normalization of hormone levels.

Vascular malformations such as arteriovenous malformations (AVMs): Complete obliteration of AVMs takes place in 78 percent of patients taking anywhere from six months to three years – average time to occlusion is two years in which 80-90 percent of AVMs will be completely obliterated.

Back to Top